CROS NT Launches CROScheck at DIA Chicago
CHAPEL HILL, NC- Jun 20, 2017 - CROS NT, a global Clinical Research Organization (CRO), announced CROScheck™, a clinical trial solution to deliver sponsors the biometrics oversight needed to assess data integrity from multiple sites. By incorporating data management and statistical methodology along with technology, sponsors can take a modular or full risk-based approach.
Visit CROS NT at DIA Booth #1040 to learn more about how CROScheck™ addresses the challenges that Sponsors encounter within the new GCP E6(R2) Guidelines that have recently come into effect. This is especially important as the guidelines state that the ultimate responsibility for the quality and integrity of the trial data will always reside with the sponsor even if fully outsourced to a CRO.
"CROScheck™ brings together leading edge intellectual property, powerful technology and world class expertise to service a growing need across our customer base. It gives Sponsors the necessary oversight and confidence to meet global regulatory requirements,” said Andrew MacGarvey, CEO of CROS NT. “Central monitoring is increasingly becoming a critical component of clinical studies. CROScheck™ will allow our customers to focus resources and budget in the most effective way," he added.
ABOUT CROS NT
Founded in 1992, CROS NT is a data-driven Contract Research Organization (CRO) providing services from feasibility to clinical study reporting for Phases I-IV and medical device trials. CROS NT's services include regulatory consultancy, monitoring, data management, biostatistics programming & analysis, pharmacovigilance, and medical writing-and accompanying eClinical applications (data visualization, EDC, IWRS, eCOA/ePRO etc.). All services are underpinned by clinical and biometrics project management with offices located in Europe, the USA and India.
Media Contact:
Dawn Fontaine
Ripple Effect Communications
dawn@rippleeffectpr.com
508-353-3777
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
